Concord Biotech Reports 14% Revenue Growth in Q3 FY26, Injectable Facility Gets WHO GMP Certification
Published on: Feb. 18, 2026, 7:41 p.m. | Source: scanx.trade
Concord Biotech Limited reported Q3 FY26 revenues of ₹278 crores, marking 14% year-on-year growth, with API business driving performance through 24% growth to ₹219 crores. The company's injectable facility received WHO GMP certification with ₹600 crores peak revenue potential, while nine-month revenues declined 5% due to first-half challenges including U.S. tariff uncertainties and regulatory delays. EBITDA margins stood at 35.60%, impacted by injectable facility commercialization costs, with management expressing optimism for Q4 performance and normalized growth returning in FY27.
